[April 20, 2018]

Immune Checkpoints Activators 2018 - Competitive Landscape, Technology and Pipeline Analysis - ResearchAndMarkets.com

The "Immune Checkpoints Activators - Competitive Landscape, Technology and Pipeline Analysis, 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.

The report provides the detailed analysis of 80+ products along with 45+ companies involved. Memgen has been granted Orphan drug designation from US-FDA for ISF 35 for the treatment of stage IIb through IV melanoma.

Products Covered by Phase

• Phase II and Phase I
• Pre-clinical and Discovery
• Inactive (Dormant and Discontinued)

Scope

• The report provides competitive pipeline landscape of Immune Checkpoints Activators
• The report provides the marketed drugs information including its sales, development activities and details of patent expiry
• The report provides the insight of current and future market for Immune Checkpoints Activators
• The report provides pipeline products under drug profile section which includes product description, MOA, icensors & collaborators, development partner and chemical information
• Coverage of the Immune Checkpoints Activators pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
• The report reviews key players involved in the therapeutics development for Immune Checkpoints Activators and also provide company profiling
• Pipeline products coverage based on various stages of development ranging from mid stage till discovery stages
• Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

• AbbVie
• Abeome Corporation
• Alligator Bioscience AB
• Alpine Immune Sciences
• Amgen
• AP Biosciences
• Apogenix
• BioInvent
• Bristol-Myers Squibb
• Celldex
• Crystal Bioscience
• Daiichi Sankyo
• DNAtrix
• Five Prime Therapeutics
• Genentech
• Genmab
• GlaxoSmithKline
• Glenmark Pharmaceuticals
• Janssen Biotech
• MedImmune
• Memgen
• Merck
• Moderna Therapeutics
• Nanjing Galaxy Biopharmaceutical
• Nektar Therapeutics
• Novartis
• OncoMed Pharmaceuticals
• Pfizer
• Pieris Pharmaceuticals
• rEVO Biologics
• Roche
• Sanofi
• Seattle Genetics
• Sorrento Therapeutics
• TheraMAB

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/c8n6b5/immune?w=4

View source version on businesswire.com: https://www.businesswire.com/news/home/20180420005697/en/

[ Back To TMCnet.com's Homepage ]